Hyloris has launched its Maxigesic IV value-added medicine in Germany and Austria, taking to five its total number of commercialized markets for the non-opioid intravenous analgesic.
Belgian value-added medicines specialist Hyloris Pharmaceuticals has announced the launch of its Maxigesic IV (paracetamol/ibuprofen) 1,000mg/300mg non-opioid treatment for post-operative pain in Germany and Austria, marking the first European launches for the intravenous analgesic.
The launches come shortly after Hyloris struck a €5.75m ($6.85m) deal to renegotiate its licensing agreement with Alter Pharma Group,...
Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.
After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024.
From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.
Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.
Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.
